UCLA Researchers have developed a novel mouse model for prostate cancer
which will be useful for preclinical trials and biochemical assays. The
mouse model is unique in that it incorporates a naturally occuring oncogene
implicated in a significant fraction of human prostate cancer and accurately
reflects the gradual progression of human prostate cancer from prostatic
intraepithelial neoplasia (PIN) to localized adenocarcinoma, to locally
invasive disease and metastatis, with essentially 100% penetrance. The time
course of disease progression allows therapeutic testing against all stages
of disease, including prevention strategies. The model offers significant
advantages over current transgenic prostate cancer models such as TRAMP,
which require expression of the SV40 T antigen and generate mice with a
large percentage of neuroendocrine, rather than adenocarcinomas of the
prostate.
Reference: UCLA Case No. 2002-135
For additional technical details and current licensing availability,
please contact the following UCLA office:
C-MYC TRANSGENIC MOUSE